About: Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times
Creator	Chan, Reddy, Brownstone, Nicholas Bridget, A Liao, Myers, Quinn, G Stephanie, Y Thibodeaux, Tina, Bhutani Vidhatha, D
Source	Medline; PMC
abstract	With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit–risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient’s individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.
has issue date	2020-04-16(xsd:dateTime)
bibo:doi	10.1007/s13555-020-00377-9
bibo:pmid	32297223
has license	no-cc
sha1sum (hex)	8942fc20e74a4b2ed1014da70253323d4bf88b49
schema:url	https://doi.org/10.1007/s13555-020-00377-9
resource representing a document's title	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times
has PubMed Central identifier	PMC7160052
has PubMed identifier	32297223
schema:publication	Dermatol Ther (Heidelb)
resource representing a document's body	covid:8942fc20e74a4b2ed1014da70253323d4bf88b49#body_text
is schema:about of	named entity 'Therapy' named entity 'COVID' named entity 'Infection' named entity 'sinusitis' named entity 'Pfizer' named entity 'infection prevention' named entity 'immunosuppressive medications' named entity 'methotrexate' named entity 'infection' named entity 'long-term' named entity 'viral disease' named entity 'psoriasis' named entity 'diabetes' named entity 'long-term' named entity 'immunosuppressive' named entity 'Merck' named entity 'coronavirus infection' named entity 'infection' named entity 'COVID-19 virus' named entity 'fever' named entity 'post-surgical' named entity 'phase III clinical trial' named entity 'hand washing' named entity 'necrosis' named entity 'infection' named entity 'psoriasis' named entity 'upper respiratory infection' named entity 'biologic therapy' named entity 'Creative Commons licence' named entity 'cellulitis' named entity 'biologics' named entity 'biologics' named entity 'coronavirus disease' named entity 'diarrhea' named entity 'infection' named entity 'COVID-19 test' named entity 'infection' named entity 'IL-17' named entity 'psoriasis' named entity 'psoriasis' named entity 'pyelonephritis' named entity 'cardiovascular disease' named entity 'fever-reducing' named entity 'COVID-19' named entity 'Creative Commons licence' named entity 'sputum production' named entity 'biologics' named entity 'shortness of breath' named entity 'psoriasis' named entity 'Celgene' named entity 'guselkumab' named entity 'respiratory symptoms' named entity 'Amgen' named entity 'COVID' named entity 'fever' named entity 'infection' named entity 'immunosuppressive medications' named entity 'lung disease' named entity 'hypertension' named entity 'ICMJE' named entity 'COVID-19 viral pandemic' named entity 'infection' named entity 'COVID-19' named entity 'inflammation' named entity '3, 4' named entity 'psoriasis' named entity 'diabetes' named entity 'COVID' named entity 'Open Access' named entity 'etanercept' named entity 'biologic agents'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software